Nature Communications (Dec 2020)
Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome
- Yeon Hee Park,
- Samir Lal,
- Jeong Eon Lee,
- Yoon-La Choi,
- Ji Wen,
- Sripad Ram,
- Ying Ding,
- Soo-Hyeon Lee,
- Eric Powell,
- Se Kyung Lee,
- Jong Han Yu,
- Keith A. Ching,
- Jae-Yong Nam,
- Seok Won Kim,
- Seok Jin Nam,
- Ji-Yeon Kim,
- Soo Youn Cho,
- Seri Park,
- Jinho Kim,
- Soohyn Hwang,
- Yu Jin Kim,
- Vinicius Bonato,
- Diane Fernandez,
- Shibing Deng,
- Shuoguo Wang,
- Hyuntae Shin,
- Eun-Suk Kang,
- Woong-Yang Park,
- Paul A. Rejto,
- Jadwiga Bienkowska,
- Zhengyan Kan
Affiliations
- Yeon Hee Park
- Samsung Medical Center
- Samir Lal
- Oncology Research & Development, Pfizer
- Jeong Eon Lee
- Samsung Medical Center
- Yoon-La Choi
- Samsung Medical Center
- Ji Wen
- Oncology Research & Development, Pfizer
- Sripad Ram
- Drug Safety R&D, Pfizer
- Ying Ding
- Oncology Research & Development, Pfizer
- Soo-Hyeon Lee
- Pfizer Oncology
- Eric Powell
- Oncology Research & Development, Pfizer
- Se Kyung Lee
- Samsung Medical Center
- Jong Han Yu
- Samsung Medical Center
- Keith A. Ching
- Oncology Research & Development, Pfizer
- Jae-Yong Nam
- Samsung Medical Center
- Seok Won Kim
- Samsung Medical Center
- Seok Jin Nam
- Samsung Medical Center
- Ji-Yeon Kim
- Samsung Medical Center
- Soo Youn Cho
- Samsung Medical Center
- Seri Park
- Samsung Medical Center
- Jinho Kim
- Samsung Genome Institute, Samsung Medical Center
- Soohyn Hwang
- Samsung Medical Center
- Yu Jin Kim
- Samsung Medical Center
- Vinicius Bonato
- Biostatistics, Pfizer
- Diane Fernandez
- Oncology Research & Development, Pfizer
- Shibing Deng
- Biostatistics, Pfizer
- Shuoguo Wang
- Oncology Research & Development, Pfizer
- Hyuntae Shin
- Samsung Genome Institute, Samsung Medical Center
- Eun-Suk Kang
- Samsung Medical Center
- Woong-Yang Park
- Samsung Genome Institute, Samsung Medical Center
- Paul A. Rejto
- Oncology Research & Development, Pfizer
- Jadwiga Bienkowska
- Oncology Research & Development, Pfizer
- Zhengyan Kan
- Oncology Research & Development, Pfizer
- DOI
- https://doi.org/10.1038/s41467-020-19933-0
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 14
Abstract
Neoadjuvant chemotherapy is a therapeutic option for the treatment of breast cancer. Here, the authors characterize changes in the gene expression profiles and immune microenvironment in serial breast cancer biopsies taken before, during and after neoadjuvant chemotherapy.
